Pretzel is developing treatments to address the genetic roots of mitochondrial dysfunction.
Pretzel was founded by some of the world’s foremost academics in mitochondrial biology, and we benefit from the leadership of accomplished experts in drug discovery, drug development, and company formation.
Our name is inspired by the focal point of our science, the mitochondrion, whose highly folded inner membrane is one of many fascinating features that make it unlike any other organelle in the body.
IO Biotech is developing immune therapies i.e. checkpoint/cancer vaccines as new cancer therapies working synergistically with existing therapy.
The company is founded by leading clinical researches at Herlev Hospital in Denmark who showed in clinical trials in lung cancer patients that their proprietary checkpoint/cancer vaccines provided more than 3x increased survival. The company’s lead program is in phase II in melanoma, and additional programs targets head and neck cancers, lung cancer as well as other cancer indications.
Galecto Biotech develops new therapies for fibrotic diseases and inflammation based on inhibition of Galectins.
The Company is based on seminal research from Lund University, Sweden, exploring the role of a group of proteins called Galectins. The lead program is in late stage clinical development and addresses a novel therapeutic target for Ideopatic Pulmonary Fibrosis called Galectin-3. Additional programs targets other fibrotic diseases. Galecto listed on NASDAQ (US) in October 2020 and trades under the ticker symbol GLTO.
ISD-Immunotech is developing a first-in-class therapy to treat the most severe Systemic lupus erythematosus (SLE) patients.
ISD-Immunotech is developing a first-in-class therapy to treat the most severe Systemic lupus erythematosus (SLE) patients. The therapy works by dampening the action of an intracellular protein called STimulator of INterferon Genes (STING). STING is part of the innate immune system, the body’s first line of defense against pathogen invaders like bacteria and viruses.
one-carbon Tx is specialized in targeting proteins involved in one carbon metabolism and DNA damage and repair (DDR) as a way to induce cancer cell death.
Co-founded by the Helleday Laboratory at SciLifeLab and Karolinska Institutet in Sweden, the company’s scientific idea is based on seminal research in DDR synthetic lethal biology by one of the leading research groups in the area. one-carbon Tx is developing first-in-class inhibitors targeting MTHFD2, an oncofetal protein expressed during embryogenesis, silenced in adult cells and then re-expressed in cancer. The lead program targets a range of cancer indications including leukemias and solid tumors with significant unmet medical needs and market potential.
Synklino develops a new treatment that can eradicate CMV virus infection, a significant problem in transplant patients.
The company is based on research from Copenhagen University and the Technical University of Denmark. Synklino’s lead molecule, Syn002, targets a receptor called US28, which is expressed by cells infected with CMV virus. US28 is found in both latent and lytic infection, and thus Syn002 provide an effective treatment in all stages of the disease. The program is currently in pre-clinical development.
Sortina develops new first in class therapies for treatment of aggressive cancers such as triple negative breast cancer.
Sortina is a spin-out of Gotenborg University. The company develops new first in class therapies inhibiting sortilins, a group of molecules playing a key role in metastasis and growth of aggressive cancers. Sortina is currently in early development, optimizing its small molecule sortilin inhibitors before entering pre-clinical studies.